SCHEMBL6565154

SCHEMBL6565154

CCCS(=O)(=O)NCCc1ccc(CCNS(=O)(=O)CCC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 6/20 0.49
HTT P42858 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
LMNA P02545 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 3/20 0.47
HSD17B10 Q99714 3/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 2/20 0.46
TBXAS1 P24557 1/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA9 Q16790 3/20 0.46
CA12 O43570 2/20 0.46
CA5A P35218 1/20 0.46
CA14 Q9ULX7 1/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6563391 0.93 MEN1 (0.54) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6563319 0.89 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6562912 0.89 MEN1 (0.57) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6762116 0.88 MAPT (0.49) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL5186030 0.88 L3MBTL1 (0.42) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6921916 0.87 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6766142 0.86 LMNA (0.51) SMN1; SMN2ALDH1A1HTTKMT2ALMNA
SCHEMBL6766169 0.86 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL6563308 0.84 GRIA4 (0.56) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL2409884 0.84 L3MBTL1 (0.53) L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 SMN1; SMN2 208/4885ALDH1A1 270/4885HTT 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.